UA138108U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

A method for predicting the development of osteoarthritis, in which a clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, transforming growth factor beta 1 (TGF- (1), interleukin 6 (IL-6), C-reactive protein (SRP) and homozygous 786-SS, thrombomodulin levels> 5 ng / ml, TGF-T1 <14 ng / ml, IL-6> 10 ng / l, PSA> 6 mg / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, the polymorphism of the nitric oxide synthase gene (6eMOb5 17860), the content of thrombomodulin, transforming growth factor beta 1 (TGF-VDI1), interleukin 6 (IL-b6), is determined in the patient's blood serum. C-reactive protein (SRP) and homozygous carrier 786-SS, thrombomodulin levels 25 ng/ml, TFR-D1 "14 ng/ml, IL-6 "10 ng/l, SRP "6b mg/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the eMO5 1786C gene polymorphism is determined, the thrombomodulin content is determined by the immunoenzymatic method,

TFR-B1, IL-6, SRP. With homozygous carrier 786-SS and thrombomodulin levels »5 ng/ml,

TFR-D1 "14 ng/ml, IL-b6 "10 ng/l, SRP "b mg/l predict the development of osteoarthritis.

A specific example of using the method.

Patient M., 60 years old, was hospitalized in the clinic due to pain syndrome of the left hip joint. Examined, x-ray taken. No signs of osteoarthritis were found. The eMO5 1786C gene polymorphism and the content of thrombomodulin, TGF-R1I, IL-6, and SRP were determined in the serum. Homozygous carrier 786-SS was established, thrombomodulin levels - 11 ng/ml, TFR-B1-9 ng/ml, IL-6-23 ng/l, PSA - 13 mg/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Coo)

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, in which a clinical examination and radiography are performed, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (EMO5 T786C), the content of thrombomodulin, transforming growth factor beta 1 (TGF-RI) is additionally determined in the patient's blood serum , interleukin 6 (IL-6), C-reactive protein (CRP) and with homozygous carrier 786-SS, thrombomodulin levels "5 ng/ml, TGF-D1 "14 ng/ml, IL-6 510 ng/l, CRP »6 mg/l predict the development of osteoarthritis. 0 Computer keyboard. Matselod 00000000 777 Ministry of Economic Development, Trade and Agriculture of Ukraine, (0000000 12/2 M. Hrushevsky St., Kyiv, 01008, Ukraine SE "Ukrainian Institute of Intellectual Property", Glazunova St., 1, Kyiv - 42, 01601